Mink Brook Asset Management LLC Takes $6.07 Million Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Mink Brook Asset Management LLC acquired a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 455,805 shares of the company's stock, valued at approximately $6,071,000. Eton Pharmaceuticals accounts for 5.8% of Mink Brook Asset Management LLC's portfolio, making the stock its 7th largest holding. Mink Brook Asset Management LLC owned approximately 1.75% of Eton Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ETON. Cannell Capital LLC acquired a new position in Eton Pharmaceuticals during the fourth quarter valued at $5,079,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in Eton Pharmaceuticals by 230.5% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,878 shares of the company's stock valued at $2,862,000 after purchasing an additional 149,864 shares during the period. Millennium Management LLC acquired a new position in Eton Pharmaceuticals during the fourth quarter valued at $1,850,000. Nantahala Capital Management LLC lifted its position in Eton Pharmaceuticals by 12.0% during the fourth quarter. Nantahala Capital Management LLC now owns 1,118,483 shares of the company's stock valued at $14,898,000 after purchasing an additional 119,750 shares during the period. Finally, Renaissance Technologies LLC lifted its position in Eton Pharmaceuticals by 131.5% during the fourth quarter. Renaissance Technologies LLC now owns 193,100 shares of the company's stock valued at $2,572,000 after purchasing an additional 109,700 shares during the period. Institutional investors and hedge funds own 27.86% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Craig Hallum upped their price objective on Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a "buy" rating in a research report on Wednesday, March 19th. B. Riley restated a "buy" rating and issued a $24.00 price objective (up previously from $21.00) on shares of Eton Pharmaceuticals in a research report on Wednesday, March 19th. Finally, HC Wainwright reiterated a "buy" rating and set a $33.00 target price on shares of Eton Pharmaceuticals in a research report on Wednesday, March 19th.

Eton Pharmaceuticals Stock Up 3.3%

Shares of ETON opened at $17.35 on Tuesday. Eton Pharmaceuticals, Inc. has a 52-week low of $3.18 and a 52-week high of $18.41. The company has a market capitalization of $465.29 million, a PE ratio of -78.86 and a beta of 1.22. The stock has a fifty day simple moving average of $14.50 and a two-hundred day simple moving average of $13.69.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last issued its earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.02). The business had revenue of $11.65 million during the quarter, compared to the consensus estimate of $10.53 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. As a group, equities analysts anticipate that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current fiscal year.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.